XMRV was discovered in the laboratories of
Joseph DeRisi at the
University of California, San Francisco, and Robert Silverman and Eric Klein of the
Cleveland Clinic. Silverman had previously
cloned and investigated the enzyme
ribonuclease L (RNase L), part of the cell's natural defense against viruses. When activated, RNase L degrades cellular and viral
RNA to halt viral replication. In 2002, the "hereditary prostate cancer 1" locus (HPC1) was mapped to the RNase L gene, implicating it in the development of prostate cancer. The cancer-associated "R462Q" mutation results in a
glutamine instead of an
arginine at position 462 of the RNase L enzyme, reducing its catalytic activity. A man with two copies of this mutation has twice the risk of prostate cancer; one copy raises the risk by 50%. Klein and Silverman hypothesized that "the putative linkage of RNase L alterations to HPC might reflect enhanced susceptibility to a viral agent" and conducted a viral screen of prostate cancer samples, leading to the discovery of XMRV. ==Disease association studies==